These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21528479)

  • 41. Modulation of alternative splicing by anticancer drugs.
    Rehman SU; Husain MA; Sarwar T; Ishqi HM; Tabish M
    Wiley Interdiscip Rev RNA; 2015; 6(4):369-79. PubMed ID: 25914287
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A review of mismatch repair gene transcripts: issues for interpretation of mRNA splicing assays.
    Thompson BA; Martins A; Spurdle AB
    Clin Genet; 2015 Feb; 87(2):100-8. PubMed ID: 24989436
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alternative splicing and cell survival: from tissue homeostasis to disease.
    Paronetto MP; Passacantilli I; Sette C
    Cell Death Differ; 2016 Dec; 23(12):1919-1929. PubMed ID: 27689872
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Connecting the dots: chromatin and alternative splicing in EMT.
    Warns JA; Davie JR; Dhasarathy A
    Biochem Cell Biol; 2016 Feb; 94(1):12-25. PubMed ID: 26291837
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aberrant and alternative splicing in cancer.
    Venables JP
    Cancer Res; 2004 Nov; 64(21):7647-54. PubMed ID: 15520162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aberrant and alternative splicing in skeletal system disease.
    Fan X; Tang L
    Gene; 2013 Oct; 528(1):21-6. PubMed ID: 23800666
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evolution of alternative splicing: deletions, insertions and origin of functional parts of proteins from intron sequences.
    Kondrashov FA; Koonin EV
    Trends Genet; 2003 Mar; 19(3):115-9. PubMed ID: 12615001
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protein kinase A alterations in endocrine tumors.
    Yu B; Ragazzon B; Rizk-Rabin M; Bertherat J
    Horm Metab Res; 2012 Sep; 44(10):741-8. PubMed ID: 22752956
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alternative splicing of iodothyronine deiodinases in pituitary adenomas. Regulation by oncoprotein SF2/ASF.
    Piekielko-Witkowska A; Kedzierska H; Poplawski P; Wojcicka A; Rybicka B; Maksymowicz M; Grajkowska W; Matyja E; Mandat T; Bonicki W; Nauman P
    Biochim Biophys Acta; 2013 Jun; 1832(6):763-72. PubMed ID: 23462647
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations.
    Gambino G; Tancredi M; Falaschi E; Aretini P; Caligo MA
    Int J Mol Med; 2015 Apr; 35(4):950-6. PubMed ID: 25683334
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aberrant alternative splicing in breast cancer.
    Yang Q; Zhao J; Zhang W; Chen D; Wang Y
    J Mol Cell Biol; 2019 Oct; 11(10):920-929. PubMed ID: 31065692
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alternative splicing and liver disease.
    Baralle M; Baralle FE
    Ann Hepatol; 2021 Dec; 26():100534. PubMed ID: 34547477
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alternative splicing of mRNA as a mode of endocrine regulation.
    Chew SL
    Trends Endocrinol Metab; 1997 Dec; 8(10):405-13. PubMed ID: 18406830
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alternative splicing in serotonergic system: Implications in neuropsychiatric disorders.
    Latorre E; Mesonero JE; Harries LW
    J Psychopharmacol; 2019 Nov; 33(11):1352-1363. PubMed ID: 31210090
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Abnormalities in alternative splicing in diabetes: therapeutic targets.
    Dlamini Z; Mokoena F; Hull R
    J Mol Endocrinol; 2017 Aug; 59(2):R93-R107. PubMed ID: 28716821
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alternative RNA splicing: contribution to pain and potential therapeutic strategy.
    Donaldson LF; Beazley-Long N
    Drug Discov Today; 2016 Nov; 21(11):1787-1798. PubMed ID: 27329269
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Innovative Therapeutic and Delivery Approaches Using Nanotechnology to Correct Splicing Defects Underlying Disease.
    Suñé-Pou M; Limeres MJ; Moreno-Castro C; Hernández-Munain C; Suñé-Negre JM; Cuestas ML; Suñé C
    Front Genet; 2020; 11():731. PubMed ID: 32760425
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mouse models of endocrine tumours.
    Jones GN; Manchanda PK; Pringle DR; Zhang M; Kirschner LS
    Best Pract Res Clin Endocrinol Metab; 2010 Jun; 24(3):451-60. PubMed ID: 20833336
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Endocrine Cancers: Defying the Paradigms.
    Bates SE
    Clin Cancer Res; 2016 Oct; 22(20):4980. PubMed ID: 27742783
    [No Abstract]   [Full Text] [Related]  

  • 60. The role of alternative splicing in cancer drug resistance.
    Siegfried Z; Karni R
    Curr Opin Genet Dev; 2018 Feb; 48():16-21. PubMed ID: 29080552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.